Clinical Trials
10 trialsNCT00801489 2026-03-30
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT00534469 2025-12-02
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
City of Hope Medical Center
Phase 2 Completed
NCT00003405 2021-10-14
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Rush University Medical Center
Phase 2 Withdrawn
NCT02144675 2021-08-24
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT00666588 2018-05-22
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01607645 2017-03-31
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00528398 2017-02-06
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
City of Hope Medical Center
Phase 2 Completed
NCT00096148 2013-01-24
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00006122 2012-07-16
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00003758 2009-02-09
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Unknown